Kymera Therapeutics Inc
NASDAQ:KYMR

Watchlist Manager
Kymera Therapeutics Inc Logo
Kymera Therapeutics Inc
NASDAQ:KYMR
Watchlist
Price: 72.28 USD 1.72% Market Closed
Market Cap: $5.2B

Operating Margin

-750.9%
Current
Declining
by 354.4%
vs 3-y average of -396.5%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-750.9%
=
Operating Income
$-328.4m
/
Revenue
$43.7m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-750.9%
=
Operating Income
$-328.4m
/
Revenue
$43.7m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Kymera Therapeutics Inc
NASDAQ:KYMR
5.1B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
394.7B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.4B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44.1B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.5B USD
Loading...

Market Distribution

Lower than 92% of companies in the United States of America
Percentile
8th
Based on 14 112 companies
8th percentile
-750.9%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Kymera Therapeutics Inc
Glance View

Market Cap
5.2B USD
Industry
Biotechnology

Kymera Therapeutics Inc., founded in 2015, is pioneering a transformative approach to drug discovery through targeted protein degradation. At its core, the company utilizes a unique technology platform, known as Pegasus, to selectively degrade disease-causing proteins. Instead of merely inhibiting proteins as traditional drugs do, Kymera's approach is to tag specific proteins for destruction by the body's own cellular machinery. This innovative strategy opens the door to treating diseases that have previously been considered "undruggable," hence expanding the horizons of therapeutic possibilities. By designing small molecules that harness the body's natural protein degradation processes, the company is strategically focused on a wide spectrum of targets, including those implicated in oncology and autoimmune diseases. Kymera's business model leverages strategic partnerships and collaborations with established pharmaceutical players to support its research and development endeavors while also transitioning several programs into the clinical phase. These collaborations not only provide crucial funding but also validate the scientific approach underpinning its technology. The company makes money through a blend of research funding, milestone payments, and potential royalty streams from partnered programs. As it builds its pipeline, Kymera remains focused on translating groundbreaking science into real-world clinical solutions, hoping to redefine how diseases are treated at their molecular roots. Through this approach, Kymera Therapeutics is not just crafting a promising business narrative but also aiming to rewrite the future of disease eradication through novel therapeutic means.

KYMR Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-750.9%
=
Operating Income
$-328.4m
/
Revenue
$43.7m
What is Kymera Therapeutics Inc's current Operating Margin?

The current Operating Margin for Kymera Therapeutics Inc is -750.9%, which is below its 3-year median of -396.5%.

How has Operating Margin changed over time?

Over the last 3 years, Kymera Therapeutics Inc’s Operating Margin has decreased from -340.8% to -750.9%. During this period, it reached a low of -750.9% on Oct 30, 2025 and a high of -204% on Jun 30, 2024.

Back to Top